Serous Papillary Carcinoma

Serous papillary carcinoma is a type of cancer that arises from epithelial cells lining body cavities or organs, most often the ovary, fallopian tube, peritoneum, or endometrium. Under the microscope it forms finger-like (papillary) projections and produces a thin, watery fluid called serous fluid. Because it can grow on the peritoneal surface and produce abdominal fluid, it can look very similar to peritoneal mesothelioma and is sometimes confused with it.

Origin

The term combines "serous," from the Latin serum meaning the watery fluid these tumors secrete, with "papillary," from Latin papilla (nipple-like projection), describing the tumor's microscopic architecture. "Carcinoma" comes from the Greek karkinos (crab), used since Hippocrates to describe invasive epithelial cancers. The category was refined in the 20th century as pathologists distinguished serous tumors of the ovary and peritoneum from other gland-forming cancers.

Significance in Asbestos Context

Serous papillary carcinoma, particularly the primary peritoneal and ovarian forms, is the most important cancer to distinguish from peritoneal mesothelioma, because both can present with abdominal swelling, ascites, and tumor nodules studding the peritoneum. The treatments, prognosis, and legal implications are very different: peritoneal mesothelioma is strongly linked to asbestos exposure, while serous carcinomas are generally not (though some studies suggest asbestos may also raise ovarian cancer risk). Pathologists rely on immunohistochemistry (IHC) stains (such as calretinin, WT-1, D2-40, PAX8, ER, and Ber-EP4) to tell them apart, and a misdiagnosis in either direction can change both medical care and eligibility for asbestos-related compensation. If you have been told you have one of these diagnoses, it is worth confirming that a mesothelioma-experienced pathologist has reviewed your slides.

Example Sentence

After her initial biopsy was read as serous papillary carcinoma, a second opinion from a mesothelioma specialty center used additional immunostains and reclassified the tumor as epithelioid peritoneal mesothelioma, which changed both her treatment plan and her legal options.

Related Terms

Peritoneal Mesothelioma, Immunohistochemistry, Calretinin, WT-1, Ascites, Differential Diagnosis

Notes

• If you have a diagnosis of serous papillary carcinoma of the peritoneum and a history of asbestos exposure, request a second pathology opinion from a center with mesothelioma expertise (such as an NCI-designated cancer center or an established mesothelioma program).
• Ask specifically which immunohistochemical stains were used; a reliable distinction from mesothelioma usually requires at least two mesothelial markers (e.g., calretinin, WT-1, D2-40) and two carcinoma markers (e.g., Ber-EP4, MOC-31, PAX8, ER).
• Preserve all pathology reports, IHC results, and the original tissue blocks/slides. These can be re-stained later and are critical for both medical reclassification and any legal claim.
• Note that women diagnosed with ovarian or primary peritoneal serous carcinoma who had occupational or household asbestos exposure may still have potential claims; ask whether your exposure history has been documented.